Impact of a newly opened prison on an accident and emergency department

Emergency Medicine Journal

Volumn 20, Issue 1, 2003, Pages 48-51

  Boyce, Stephen H ^a   Stevenson, James ^a   Jamieson, Iain S ^b   Campbell, Stewart ^c  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

^b HMP Kilmarnock   (United Kingdom)

^c GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCIDENT; ADULT; ARTICLE; CUSTODY; DEATH; DRUG MISUSE; EAR NOSE THROAT DISEASE; EMERGENCY WARD; HEALTH CARE DELIVERY; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; MEDICAL STAFF; PATIENT REFERRAL; PRIORITY JOURNAL; PRISON; PRIVATE HOSPITAL; PROSPECTIVE STUDY; SAFETY; SPORT INJURY; SUICIDE ATTEMPT; UNITED KINGDOM; VIOLENCE; WORKLOAD;

EID: 0037258757     PISSN: 13510622     EISSN: None     Source Type: Journal    
DOI: 10.1136/emj.20.1.48     Document Type: Article

References (20)

1. Hughes RA. Health, place and British prisons. Health Place 2000, 6: 57-62.
2. Reed J, Lyne M. The quality of health care in prison: Results of a years programme of semistructured inspections. BMJ 1997;315:1420-1444
3. Levy M. Prison health services. Should be as good as those for the general community. BMJ 1997;315:1394-5.
4. Squires N. Promoting health in prisons. Requires more than a change in who purchases health services for prisoners. BMJ 1996;313:1161.
5. Smith R. Prison medicine: Beginning again. Time to hand over everything to the NHS. BMJ 1992;304:134-5.
6. Baillargeon J, Black SA, Pulvino J, et al. The disease profile of Texas prison inmates. Ann Epidemiol 2000;10:74-80.
7. Holdstock D. Shackling prisoners. Is a breach of human rights. BMJ 1996;312:200.
8. Amnesty International. Pregnant and imprisoned in the United States. Birth 2000;27:266-71.
9. Hedouin V, Gosset D. Infection with hepatitis C virus in a prison environment. A prospective study in Loos-lez-Lille, France. Gastroenterol Clin Biol 1998;22:55-8.
10. Butler TG, Dolan KA, Ferson MJ, et al. Hepatitis B and C in New South Wales prisons: Prevalence and risk factors. Med J Austr 1997;166:127-30.
11. Spaulding A, Greene C, Davidson K, et al. Hepatitis C in state correctional facilities. Prev Med 1999;28:92-100.
12. Mohsen AH. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;48:707-13.
13. Thorburn D, Dundas D, McCruden EAB, et al. A study of hepatitis C prevalence in healthcare workers in the West of Scotland. Gut 2001;48:116-20.
14. Kiyosawa K, Sodeyama T, Tanaka E. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991; 115: 367-9.
15. Mitsui T, Iwano K, Masuko K. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992;16:1109-14.
16. Poynard T, Leroy V, Cohard M. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24:778-89.
17. Farrell GC. Therapy of hepatitis C: Interferon alfa-n1 trials. Hepatology 1997;26 (suppl 1):96-100s.
18. Poynard T, Marcellin P, Lee SS. Randomised trial of interferon alpha 2b plus ribivirin for 48 weeks or for 24 weeks versus alpha 2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus. Lancet 1998;352:1426-32.
19. McHutchinson JG, Gordon SC, Schiff ER. Interferon alpha 2b alone or in combination with ribivirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1458-92.
20. Zeuzam S, Feinmann SV, Rasenack J, et al. Peginterferon alfa 2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.